Cumberland Pharmaceuticals Inc.
NASDAQ:CPIXDrug Manufacturers - Specialty & Generic
-$0.06 today
- Market cap
- $98.52M
- Beta
- 0.10
- P/E (TTM)
- -11.5
- EPS (TTM)
- -$0.48
Volume 0.16M
Average 0.97M
CPIX Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Cumberland Pharmaceuticals Inc.NASDAQ: CPIX
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit dips below year-ago levels
Q1 FY2026 gross profit of $7.2M fell 30.0% year over year, behind the +0.3% change in trailing-twelve-month gross profit. Sequentially, it fell 37.1% from the prior quarter. Over 3 fiscal years it compounded at +4.8% a year.
Context
- Gross profit amounted to 85.0% of revenue in FY2025, up 2.4 pp from a year earlier.
- Gross profit increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -30.0% toward the trailing-twelve-month pace of +0.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 37.85M USD
- Year-over-year change
- +21.0%
- 4-year CAGR
- +8.6%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 37.85M | +21.0% |
| FY2024 | 2024-12-31 | 31.28M | -6.6% |
| FY2023 | 2023-12-31 | 33.49M | +1.8% |
| FY2022 | 2022-12-31 | 32.89M | +21.0% |
| FY2021 | 2021-12-31 | 27.17M | — |
Gross Profit vs competitors
How CPIX compares with its peers on the latest reported figures
- CPIX's LTM Mar 2026 gross profit of $34.76M is the highest of the 4 companies compared; the peer median is $929.95K.
- Its year-over-year change of +0.3% is the 2nd highest of 4, against a peer median of -48.5%.
- Gross profit amounts to 82.9% of revenue for CPIX, versus a peer median of 53.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $34.76M | +0.3% | +4.8% | 82.9% | |
| LTM Dec 2025 | $20.19M | -48.5% | — | 76.0% | |
| LTM Mar 2026 | $929.95K | -53.4% | — | 31.3% | |
| LTM Mar 2026 | -$3.85K | +92.5% | — | — | |
| Peer median (excluding CPIX) | $929.95K | -48.5% | — | 53.6% | |
Competitors are the stored peer set for CPIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 35.99M | 42.01M | 39.55M | 37.87M | 44.52M |
| Cost of Revenue | 8.81M | 9.12M | 6.07M | 6.59M | 6.67M |
| Gross Profit | 27.17M | 32.89M | 33.49M | 31.28M | 37.85M |
| Gross Margin | 75.5% | 78.3% | 84.7% | 82.6% | 85.0% |
| Research & Development | 5.68M | 6.69M | 5.83M | 4.82M | 5.57M |
| Selling, General & Admin | 24.8M | 26.84M | 29.1M | 28.15M | 31.05M |
| Operating Expenses | 34.85M | 38.6M | 43.04M | 37.71M | 40.65M |
| Depreciation & Amortization | 4.61M | 5.33M | 8.1M | 6.04M | 5.29M |
| EBITDA | (857.83K) | 332.92K | 2.49M | 182.42K | 2.96M |
| EBITDA Margin | -2.4% | 0.8% | 6.3% | 0.5% | 6.6% |
| Operating Income | (7.68M) | (5.7M) | (9.55M) | (6.43M) | (2.79M) |
| Operating Margin | -21.3% | -13.6% | -24.2% | -17.0% | -6.3% |
| Interest Income | 26.08K | 98.41K | 286.85K | 334.44K | 476.75K |
| Interest Expense | 98.03K | 586K | 667.86K | 605.51K | 495.99K |
| Other Income / Expenses | 2.12M | 123.74K | 3.27M | (33.98K) | (32.46K) |
| Income Before Tax | (5.56M) | (5.58M) | (6.28M) | (6.47M) | (2.82M) |
| Pre-Tax Margin | -15.5% | -13.3% | -15.9% | -17.1% | -6.3% |
| Income Tax Expense | 34.89K | 68.85K | 45.77K | (22.67K) | 40.26K |
| Net Income | (3.51M) | (5.57M) | (6.28M) | (6.48M) | (2.84M) |
| Net Margin | -9.7% | -13.3% | -15.9% | -17.1% | -6.4% |
| EPS (Basic) | (0.24) | (0.38) | (0.44) | (0.46) | (0.19) |
| EPS (Diluted) | (0.24) | (0.38) | (0.44) | (0.46) | (0.19) |
| Weighted Avg Shares | 14.9M | 14.56M | 14.3M | 14.06M | 14.96M |
| Weighted Avg Shares (Diluted) | 14.9M | 14.56M | 14.3M | 14.06M | 14.96M |
Cumberland Pharmaceuticals Inc.
NASDAQ:CPIX
Intrinsic Alpha fair value
Locked
Current Price
$6.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.